Oppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00

Keros Therapeutics (NASDAQ:KROS) had its price target cut by Oppenheimer from $63.00 to $23.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would indicate a potential upside of 125.51% from the company’s current price.

A number of other equities research analysts also recently commented on the company. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. Scotiabank lowered their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research report on Friday, December 13th. Wells Fargo & Company lifted their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Finally, BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $70.56.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded down $0.22 during midday trading on Thursday, reaching $10.20. The stock had a trading volume of 1,444,360 shares, compared to its average volume of 2,387,313. The company has a market capitalization of $413.16 million, a price-to-earnings ratio of -1.96 and a beta of 1.43. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The stock has a 50-day moving average of $39.77 and a 200-day moving average of $47.88.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.33) earnings per share. As a group, analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after purchasing an additional 46,041 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Keros Therapeutics by 14.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after buying an additional 32,492 shares during the period. Barclays PLC grew its holdings in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Keros Therapeutics in the 3rd quarter valued at $603,000. Finally, Point72 Asset Management L.P. raised its stake in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.